2. Academic Validation
  3. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions

Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions

  • Pharmacol Rep. 2009 Mar-Apr;61(2):197-216. doi: 10.1016/s1734-1140(09)70024-6.
Jarogniew J Luszczki 1
Affiliations

Affiliation

  • 1 Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, PL 20-090 Lublin, Poland. jarogniew.luszczki@am.lublin.pl
PMID: 19443931 DOI: 10.1016/s1734-1140(09)70024-6
Abstract

This review briefly summarizes the information on the molecular mechanisms of action, pharmacokinetic profiles and drug interactions of novel (third-generation) antiepileptic drugs, including brivaracetam, carabersat, carisbamate, DP-valproic acid, eslicarbazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, and valrocemide. These novel antiepileptic drugs undergo intensive clinical investigations to assess their efficacy and usefulness in the treatment of patients with refractory epilepsy.

Figures
Products